linjc16/ctgov huggingface dataset:
The Effect of Nutritional Risk Parameters on Postoperative Pulmonary Complications in Geriatric Thoracic Surgery Cases

Study Overview
=================
Brief Summary
-----------------
Preoperative evaluation of nutritional status in geriatric patients with lung cancer and implementation of these practices in elective patients are very important in terms of reducing postoperative complications and accelerating hospital discharge. For this purpose, many nutritional assessments and measurements are used. Our aim in this study was to evaluate the relationship between preoperative nutritional status and postoperative pulmonary complications in patients undergoing thoracic surgery for geriatric lung cancer.

Official Title
-----------------
Evaluation of the Effect of Preoperative Nutritional Risk Parameters on Postoperative Pulmonary Complications in Geriatric Patients Who Underwent Lung Resection for Malignancy, a Prospective Observational Study

Conditions
-----------------
Lung Cancer, Nutrition, Healthy, Postoperative Complications

Intervention / Treatment
-----------------
* Other: Preoperative nutritional assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 65 years of age Lung Cancer Patients undergoing thoracic surgery Exclusion Criteria: Refusal to participate in the study Patients with a diagnosis of hematological malignancy Patients with missing data required for research

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FFMI - Fat-Free Mass Index | FFMI is an abbreviation for lean mass index. It defines the amount of your muscle mass relative to height and weight. The FFMI is part of the well-known and similar BMI family of body indexes. The effect of FFMI values on postoperative patient stay, intensive care unit stay, complications and postoperative mobilization time in lung cancer patients will be evaluated. Each patient will be evaluated by measuring the preoperative FFMI value 24 hours before. | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI (Body Mass Index) | BMI is a measurement of a person's leanness or corpulence based on their height and weight, and is intended to quantify tissue mass. The effect of BMI values on postoperative patient stay, intensive care unit stay, complications and postoperative mobilization time in lung cancer patients will be evaluated. Each patient will be evaluated by measuring the preoperative BMI value 24 hours before. | 24 hours |
Effectiveness of TU and MRT to Release Trigger Points to Increase RoM and Pain Relief in Upper TT

Study Overview
=================
Brief Summary
-----------------
To find out the Effectiveness of Therapeutic Ultrasound and Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness

Official Title
-----------------
Effectiveness of Therapeutic Ultrasound and Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Diagnostic Test: Therapeutic Ultrasound
* Diagnostic Test: Myofascial Release Technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Age between 20-40years. 2. Male and female both are included. 3. Those having tenderness on a taut muscle band, rise in regular pain, local twitching response, and restricted range of motion of cervical region. Exclusion Criteria: 1. Those having referred pain due to any pathology of cervical. 2. Those having any healing fractures over upper back and in neck region. 3. Those who have dermatitis over upper back or any clotting disorder. 4. Any related wound in neck region or any pathology of shoulder. 5. Those who has any degenerative cervical spine disease. (2)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Therapeutic Ultrasound<br> | Diagnostic Test: Therapeutic Ultrasound<br>* Therapeutic Ultrasound to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness<br>|
| Other: Myofascial Release Technique<br> | Diagnostic Test: Myofascial Release Technique<br>* Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numaric Pain scale Rating (NPR). | Pre and post interventions with (NPR) Scale to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness | 6 Months. |
Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules

Study Overview
=================
Brief Summary
-----------------
It is planned to use the CLE probe and cryoprobe simultaneously after detection of the round focus. It is planned to include 5 patients with suspected central airway invading lung carcinoma and 15 patients with suspected peripheral lung carcinoma who have an indication for bronchoscopic histologic confirmation.

Official Title
-----------------
Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules

Conditions
-----------------
Pulmonary Disease

Intervention / Treatment
-----------------
* Other: CLE-guided cryobiopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years Suspicion of lung carcinoma Exclusion Criteria: Known allergy to fluorescin Pregnancy and/or lactation No discontinuation of ß-blocker 12 hours before intervention possible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br> | Other: CLE-guided cryobiopsy<br>* During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and feasibility | Advers events | during bronchoscopy |
Fetal Scalp pH During Labour: is it Worth Repeating

Study Overview
=================
Brief Summary
-----------------
In order to reduce the cesarean sections rate, an adjunctive test is recommended in case of non-reassuring fetal heart rate tracing. In France, the reference adjunctive test is fetal scalp blood sampling. However, there is no study about the repetition of fetal blood sampling. Our hypothesis is that the repetition of fetal blood sampling is useful when fetal heart rate stays non-reassuring and may lead to vaginal delivery without impair neonatal prognostic. Therefore, our objective was to compare the patients with three or more fetal blood sampling with the patients with one or two.

Official Title
-----------------
Fetal Scalp pH During Labour: is it Worth Repeating

Conditions
-----------------
Abnormal Fetal Heart Rate

Intervention / Treatment
-----------------
* Diagnostic Test: Fetal blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: One fetal blood sampling during labour or more Singleton pregnancy Gestational age equal or above 37 weeks No contra-indication of fetal blood sampling No pregnancy complication Exclusion Criteria: Sampling failure Incomplete file

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pH < 3<br>Patients one or two fetal blood sampling | Diagnostic Test: Fetal blood sampling<br>* Fetal scalp blood sampling and analysis<br>|
| pH > 3<br>Patients with three or more fetal blood sampling | Diagnostic Test: Fetal blood sampling<br>* Fetal scalp blood sampling and analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delivery | Vaginal delivery, operative delivery, cesarean section | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apgar score | value of Apgar score at five minutes of life | baseline | 
| umbilical cord pH | value of umbilical cord pH | baseline | 
| umbilical cord lactates | value of umbilical cord lactates | baseline | 
| neonatal care intensive unit transfer | rate of neonatal care intensive unit transfer | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fetal scalp blood sampling, fetal blood sampling, cesarean section, non-reassuring fetal heart rate
Effect of Inhaled Nitric Oxide on Pulmonary Ventilation/Perfusion Ratio Assessed by EIT in Patients With ARDS

Study Overview
=================
Brief Summary
-----------------
Electrical impedance tomography was used to monitor changes in pulmonary perfusion distribution and V/Q ratio before and after iNO in patients with acute respiratory distress syndrome to investigate the factors predicting iNO reactivity and the physiological mechanism underlying changes in oxygenation.

Official Title
-----------------
Effect of Inhaled Nitric Oxide on Pulmonary Ventilation/Perfusion Ratio Assessed by Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrome

Conditions
-----------------
Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≥ 18 years; Patients are intubated and mechanically ventilated. Exclusion Criteria: EIT contraindications such as chest wound dressing, pacemaker installation, defibrillator, etc; With a history of cerebral hemorrhage in the past half year, as well as bleeding in any site of the body; Pneumothorax; Medium or massive pleural effusion; Refractory shock; Pregnant With chronic kidney disease Atrial fibrillation or other malignant arrhythmia leads to a decrease in cardiac output; Failure to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung ventilation/perfusion ration | Lung ventilation/perfusion ration after iNO assessed by EIT | 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung perfusion distribution | Lung ventilation/perfusion ration after iNO assessed by EIT | 30minutes and 3 hours | 
| Shunting | Lung shunting% after iNO assessed by EIT | 30minutes and 3 hours | 
| Dead space | Lung dead space after iNO assessed by EIT | 30minutes and 3 hours | 
| Oxygenation index | Oxygenation index= arterial partial pressure of oxygen/fraction of inspired oxygen | 30minutes and 3 hours | 
| Arterial partial pressure of carbon dioxide (PaCO2) | PaCO2 is one of the key indicators of pulmonary ventilation which can be obtained from arterial blood gas analysis. | 30minutes and 3 hours | 
| Static respiratory compliance (Crs) | Crs=tidal volume/driving pressure | 30minutes and 3 hours | 
| Cardiac output | Cardiac output assessed by echocardiography | 30minutes and 3 hours | 
| Right ventricular function | Right ventricular function assessed by echocardiography | 30minutes and 3 hours |
Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to explore the pathophysiological effects of the persistently colonized microbiome in irritable bowel syndrome (IBS) patients. The main questions it aims to answer are: Question 1: the microbiome difference of the biofilm between IBS and healthy patients. Question 2: the metabolic product patterns between IBS and healthy patients. Participants will need to take a colonoscopy examination, two gut mucosal biopsy samples will be collected during the examination. Researchers will compare the IBS and healthy control groups to see if there was the disease-specific pattern in the microbiome and metabolic product of the biofilm.

Official Title
-----------------
Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IBS patients with IV type; no abdominal surgery; Exclusion Criteria: age <18 y; major disease; alcoholic addicted; antibiotic use in past 3 months; severe gastrointestinal disease severe cardiac disease; pregnant; ICU in past 1 year; vegeterian; immune disease (SLE etc.) mental disease;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IBS group<br>patients diagnosed with IBS according to clinical presentations | Diagnostic Test: colonoscopy<br>* colonoscopy<br>|
| No Intervention: Healthy control group<br>healthy control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mirobiome difference of the fecal between IBS and health controls | 16S rDNA sequencing will be applied in fecal samples all the above participants | Fecal samples will be collected immediately before the colonoscopy (T1) and 7 days after the colonoscopy test (T2) | 
| mirobiome difference of the fecal between IBS and health controls | 16S rDNA sequencing will be applied in fecal samples all the above participants | Fecal samples will be collected 7 days after the colonoscopy test (T2) | 
| Metabolic changes between IBS and Healthy controls | mucosal biopsy will be collected during the colonoscopy in each patients | 1 day biopsy will be collected during the colonoscopy test |
MicroRNAs From Blood Samples as Biomarkers for Gastric Cancer Detection

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to compare specific microRNA levels from the plasma of gastric cancer patients and healthy volunteers to see if there is an upregulated expression in gastric cancer patients. The main question it aims to answer is: - Can microRNAs be effectively used as diagnostic biomarkers for gastric cancer? Participants will be asked for their consent to obtain 5 cc of blood.

Official Title
-----------------
MicroRNAs From Blood Samples as Biomarkers for Gastric Cancer Detection: a Diagnostic Study

Conditions
-----------------
Gastric Cancer, MicroRNAs

Intervention / Treatment
-----------------
* Diagnostic Test: MicroRNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for Gastric Cancer group: Recently diagnosed gastric cancer Never received any treatment for gastric cancer Inclusion Criteria for Control group: Age 50 or above Underwent elective upper gastrointestinal endoscopy and negative for gastric cancer No prior history of gastric dysplasia or cancer Exclusion Criteria: Patients who cannot give informed consent Pregnancy Lymphoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Gastric Cancer<br> | Diagnostic Test: MicroRNA<br>* MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223<br>|
| Control<br> | Diagnostic Test: MicroRNA<br>* MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The different of MiR-20a level between gastric cancer and control group | The different of MiR-20a level between gastric cancer and control group | Day 1 | 
| The different of MiR-21 level between gastric cancer and control group | The different of MiR-21 level between gastric cancer and control group | Day 1 | 
| The different of MiR-106b level between gastric cancer and control group | The different of MiR-106b level between gastric cancer and control group | Day 1 | 
| The different of MiR-199a level between gastric cancer and control group | The different of MiR-199a level between gastric cancer and control group | Day 1 | 
| The different of MiR-223 level between gastric cancer and control group | The different of MiR-223 level between gastric cancer and control group | Day 1 |
Blood Collection for COM/BSBS

Study Overview
=================
Brief Summary
-----------------
The objective of this biospecimen collection protocol is the acquisition of blood from adult volunteers. These biospecimens will be transferred to the College of Medicine (COM)/Burnett School of Biomedical Sciences (BSBS) research scientists and their research teams for testing according to their separate IRB-approved/exempted protocols. These separate IRBapproved protocols cannot be for genetic testing.

Detailed Description
-----------------
Research scientists of the University of Central Florida College of Medicine (COM) and Burnett School of Biomedical Sciences (BSBS) conduct laboratory studies in biomedical and translational research for the purpose of understanding human disease and developing innovative methods for diagnosing, measuring, or treating disease or disease symptoms. The key research divisions are cancer, cardiovascular, immunity and pathogenesis, neuroscience, and molecular microbiology. Frequently, these studies require human blood (or its derivatives) for testing of assays and devices.

Official Title
-----------------
Blood Collection for Use With Translational, Biomedical Research at UCF College of Medicine and Burnett School of Biomedical Sciences

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female adults 18 years old or older weigh over 110 pounds able to provide informed consent Exclusion Criteria: pregnant/suspect to be pregnant prisoners have donated blood anywhere in the preceding 16 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acquisition of blood samples for testing | This is a non-clinical, biospecimen collection study. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood, Healthy
A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy

Study Overview
=================
Brief Summary
-----------------
This study is a multicenter cross-sectional survey of esophageal cancer patients who underwent radical chemoradiotherapy/radiotherapy from July 2017 to July 2020 in various medical centers, and who survived without disease progression at the time of the survey. The purpose of this study is to evaluate the current quality of life, as well as the incidence of long-term toxic side effects, nutritional status, and psychological status of esophageal cancer patients cured by radiotherapy.

Official Title
-----------------
A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy

Conditions
-----------------
Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival

Intervention / Treatment
-----------------
* Other: questionnaire investigation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Voluntarily accept this survey and research; The age at the time of radiotherapy is between 18-75 years old, and the age at the time of investigation is<80 years old; Histologically confirmed esophageal squamous cell carcinoma without undergoing surgical resection; Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020, currently alive and without disease progression; Radiotherapy dose ≥ 45Gy. Exclusion Criteria: Patients who do not cooperate with this survey; Patients who have died at the time of investigation; Patients who experience tumor progression within the time frame from the end of radiotherapy to receiving this survey; Patients diagnosed with other malignant tumors within the time frame from the end of radiotherapy to receiving this survey; Patients with incorrect contact information and missing visits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Life Assessment survey |  | Two years after the end of radiotherapy |